Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

Overview of the autoimmune and inflammatory immunomodulators market

According to the market research analysts at Technavio, the autoimmune and inflammatory immunomodulators market is expected to witness fast-paced growth and will post an impressive CAGR of more than 7% during the predicted period. The development of novel therapies using innovative technologies is one of the major factors driving this market’s growth. The existing drugs in the market do not provide a complete cure for irritable bowel syndrome (IBS) and rheumatoid arthritis. Several research studies have also indicated that nearly one-third of the patients suffering from IBS and undergoing conventional treatment do not respond these drugs. This has led to increased focus on research activities by the vendors with the use of novel technologies for the development of therapies that will provide complete remission of the disease. For instance, Txcell is developing Ovasave by using ASTrIA technology platform for the treatment of IBD such as Crohn’s disease. This technology utilizes antigen-specific Type 1 Treg cells, which recognize the specific antigen at the inflammation site and suppresses the immune responses.

In terms of geography, the Americas led the market and will continue to dominate the market over the coming years. The US was the major revenue contributor and accounted the majority of market shares in the region. The healthcare reforms of various countries are showing a positive impact on the market growth. For example, in the US, the implementation of the Affordable Care Act (ACA) is rapidly changing the business environment for pharmaceuticals. Healthcare reforms in the country have considerably reduced the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms can have a positive impact on healthcare insurance and reduce hospital stay and overall medical expenses, thereby contributing this market’s growth in the region.

Competitive landscape and key vendors

The global autoimmune and inflammatory immunomodulators market is highly consolidated with key players including AbbVie, Johnson & Johnson, and Amgen, which together account for the majority of market shares. The vendors are focusing on opportunities in emerging markets such as China and India to increase their market share.

Key vendors in this market are -

• AbbVie
• Johnson & Johnson
• Amgen
• F. Hoffmann-La Roche
• Pfizer

Other prominent vendors in the market include AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Enlivex Therapeutics, Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Neovacs, Prometheus Laboratories, Sandoz, Sanofi, Swedish Orphan Biovitrum, Takeda Pharmaceuticals, and UCB.

Segmentation by type of disease and analysis of the autoimmune and inflammatory immunomodulators market

• Rheumatoid arthritis
• IBD

During 2015, the rheumatoid arthritis segment dominated the market and will continue to the lead the market over the coming years. The rise in public awareness is a major factor contributing this market’s growth. Several organizations like National Rheumatoid Arthritis Society, Arthritis National Research Foundation, Rheumatoid Patient Foundation in the US, Arthritis Foundation of India Trust and Indian Rheumatology Association in India, and International Foundation for Autoimmune Arthritis are actively involved in spreading the knowledge about the disease among patients, their family, and the public. These organizations conduct various events like seminars, webinars, and exhibitions to increase the awareness about the disease, which will also boost this market segment’s growth.

Segmentation by molecule type and analysis of the immunomodulators market

• Biologics
• Small molecules

The global autoimmune and inflammatory biologic immunomodulators segment accounted for the majority of market shares and will lead the market until the end of 2020. Biologic drugs used for the treatment of rheumatoid arthritis are made from proteins. They work by blocking the action of key chemicals in the body that is involved in inflammation, swelling of joints, and other symptoms. Also, biologics are highly effective in the treatment of rheumatoid arthritis. Moreover, the increasing use of biologics in drugs development will contribute to this segment’s growth.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global autoimmune and inflammatory immunomodulators market?
• What are the key market trends impacting the growth of the global autoimmune and inflammatory immunomodulators market?
• What are the challenges to market growth?
• Who are the key vendors in the global autoimmune and inflammatory immunomodulators market?
• What are the market opportunities and threats faced by the vendors in the global autoimmune and inflammatory immunomodulators market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global autoimmune and inflammatory immunomodulators market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Inflammatory Bowel Disease Market 2015-2019
• Global Musculoskeletal Disorders Therapeutics Market 2016-2020
• Global Rheumatoid Arthritis Drugs Market 2016-2020
• Global mAb Biosimilars Market 2016-2020